Vistagen Therapeutics Stock Price Prediction
| VTGN Stock | USD 0.62 0.03 4.62% |
Momentum 25
Sell Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0.32) | EPS Estimate Current Year (1.83) | EPS Estimate Next Year (1.23) | Wall Street Target Price 0.9667 | EPS Estimate Current Quarter (0.44) |
Using VistaGen Therapeutics hype-based prediction, you can estimate the value of VistaGen Therapeutics from the perspective of VistaGen Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards VistaGen Therapeutics using VistaGen Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards VistaGen using crowd psychology based on the activity and movement of VistaGen Therapeutics' stock price.
VistaGen Therapeutics Short Interest
An investor who is long VistaGen Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about VistaGen Therapeutics and may potentially protect profits, hedge VistaGen Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 2.8097 | Short Percent 0.1224 | Short Ratio 0.59 | Shares Short Prior Month 1.8 M | 50 Day MA 2.5072 |
VistaGen Therapeutics Hype to Price Pattern
Investor biases related to VistaGen Therapeutics' public news can be used to forecast risks associated with an investment in VistaGen. The trend in average sentiment can be used to explain how an investor holding VistaGen can time the market purely based on public headlines and social activities around VistaGen Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of VistaGen Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about VistaGen Therapeutics.
VistaGen Therapeutics Implied Volatility | 1.56 |
VistaGen Therapeutics' implied volatility exposes the market's sentiment of VistaGen Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if VistaGen Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that VistaGen Therapeutics stock will not fluctuate a lot when VistaGen Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in VistaGen Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying VistaGen because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
VistaGen Therapeutics after-hype prediction price | USD 0.6 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out VistaGen Therapeutics Basic Forecasting Models to cross-verify your projections. VistaGen Therapeutics After-Hype Price Density Analysis
As far as predicting the price of VistaGen Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in VistaGen Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of VistaGen Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
VistaGen Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting VistaGen Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on VistaGen Therapeutics' historical news coverage. VistaGen Therapeutics' after-hype downside and upside margins for the prediction period are 0.03 and 12.47, respectively. We have considered VistaGen Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
VistaGen Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of VistaGen Therapeutics is based on 3 months time horizon.
VistaGen Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as VistaGen Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading VistaGen Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with VistaGen Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.51 | 11.87 | 0.02 | 0.25 | 6 Events / Month | 6 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.62 | 0.60 | 3.23 |
|
VistaGen Therapeutics Hype Timeline
VistaGen Therapeutics is at this time traded for 0.62. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of -0.25. VistaGen is forecasted to decline in value after the next headline, with the price expected to drop to 0.6. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -3.23%, whereas the daily expected return is at this time at -1.51%. The volatility of related hype on VistaGen Therapeutics is about 7193.94%, with the expected price after the next announcement by competition of 0.37. About 58.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.38. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 1.92. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. Given the investment horizon of 90 days the next forecasted press release will be in about 6 days. Check out VistaGen Therapeutics Basic Forecasting Models to cross-verify your projections.VistaGen Therapeutics Related Hype Analysis
Having access to credible news sources related to VistaGen Therapeutics' direct competition is more important than ever and may enhance your ability to predict VistaGen Therapeutics' future price movements. Getting to know how VistaGen Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how VistaGen Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SPRO | Spero Therapeutics | (0.04) | 9 per month | 2.67 | 0 | 3.64 | (5.04) | 13.07 | |
| SEER | Seer Inc | 0.01 | 8 per month | 0.00 | (0.12) | 3.41 | (3.06) | 9.98 | |
| MCRB | Seres Therapeutics | (1.12) | 9 per month | 0.00 | (0.02) | 9.13 | (7.64) | 54.10 | |
| IRD | Opus Genetics | 0.01 | 10 per month | 3.57 | 0.09 | 6.70 | (6.10) | 26.50 | |
| CGTX | Cognition Therapeutics | 0.17 | 12 per month | 0.00 | (0.07) | 8.89 | (8.38) | 24.96 | |
| HURA | TuHURA Biosciences | (0.05) | 12 per month | 0.00 | (0.24) | 7.73 | (10.53) | 50.34 | |
| AGEN | Agenus Inc | 0.11 | 9 per month | 0.00 | (0.11) | 6.63 | (6.79) | 30.06 | |
| ACTU | Actuate Therapeutics Common | (0.61) | 5 per month | 0.00 | (0.12) | 5.40 | (6.74) | 20.01 | |
| ABOS | Acumen Pharmaceuticals | 0.04 | 8 per month | 4.54 | 0.02 | 9.94 | (7.18) | 25.06 | |
| INO | Inovio Pharmaceuticals | (0.17) | 9 per month | 0.00 | (0.11) | 6.87 | (6.80) | 36.52 |
VistaGen Therapeutics Additional Predictive Modules
Most predictive techniques to examine VistaGen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for VistaGen using various technical indicators. When you analyze VistaGen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About VistaGen Therapeutics Predictive Indicators
The successful prediction of VistaGen Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as VistaGen Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of VistaGen Therapeutics based on analysis of VistaGen Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to VistaGen Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to VistaGen Therapeutics's related companies. | 2025 | 2026 (projected) | Payables Turnover | 0.0505 | 0.0534 | Days Of Inventory On Hand | 829.89 | 737.69 |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with VistaGen Stock
Moving against VistaGen Stock
| 0.84 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.76 | DBVT | DBV Technologies | PairCorr |
| 0.76 | MARUF | Marubeni | PairCorr |
| 0.74 | HLN | Haleon plc Aggressive Push | PairCorr |
| 0.69 | CAPR | Capricor Therapeutics | PairCorr |
| 0.67 | CNOB | ConnectOne Bancorp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out VistaGen Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.